Authors

Latest:

Dr. Patterson on Off-Target Effects With TKIs in Pediatric CML

Briana Patterson, MD, assistant professor, Division of Endocrinology, Aflac Cancer Center, Department of Pediatrics, Emory University School of Medicine, discusses the off-target effects with tyrosine kinase inhibitors (TKIs) in pediatric patients with chronic myeloid leukemia (CML).

Brice Labruzzo Mohundro, PharmD

Latest:

On the Horizon for Multiple Myeloma: Update on Novel Agents, Bone Therapies

A new generation of proteasome inhibitors, immunomodulatory agents, and deacetylase inhibitors are currently being investigated in clinical trials to treat patients with relapsed or refractory multiple myeloma.

Bridget F. Koontz, MD

Latest:

Dr. Koontz on Next Steps for Study of LHRH in Prostate Cancer

Bridget F. Koontz, MD, radiation oncologist, Duke Cancer Institute, discusses the next steps for the phase II trial of 6 months of androgen deprivation therapy/abiraterone acetate (Zytiga) plus prednisone and definitive radiotherapy for men with intermediate- to high-risk localized prostate cancer.

Bridgett Harr, CNP

Latest:

Bridgett Harr on Managing Long-term Side Effects in Head and Neck Cancer

Bridgett Harr, CNP, radiation oncology, Cleveland Clinic, discusses survivorship and managing long-term side effects in head and neck cancer.

Brielle Benyon

Latest:

Rewriting the Rules for a Better Future of Cancer Care

Confidence, support, and hard work paved the way for an exceptionally successful career for Edward S. Kim, MD, MBA, who has a cemented mission in diversifying clinical trials and improving quality of life.

Brielle Urciuoli

Latest:

Persistence and the Quest for Innovation Guided a Radiotherapy Pioneer

Herman D. Suit, MD, MSc, PhD, a leader in the field of radiation oncology whose innovations lessened the need for radical surgery and improved outcomes for patients, was honored in the Radiation Oncology category with a 2017 Giants of Cancer Care® award.

Brielle Uricioli

Brigid Killelea, MD, MPH, FACS

Latest:

Dr. Brigid Killelea on Nipple-Sparing Mastectomy for Breast Cancer

Brigid Killelea, MD, MPH, FACS, associate professor of surgery (oncology), Yale Cancer Center, discusses the potential of nipple-sparing mastectomy for women who undergo surgery for breast cancer.

Brigitta Torster

Latest:

NO-Naproxen May Protect Against Colorectal Cancer

A study presented at the AACR 101st Annual Meeting 2010 by researchers from the Fox Chase Cancer Center, Philadelphia, Pennsylvania, provides further evidence that non-steroidal anti-inflammatory drugs (NSAIDs) are promising chemopreventive agents with activity against colorectal cancer.

Bristi Basu, MD

Latest:

Dr. Basu on Second-Line Therapy in HCC

Bristi Basu, MD, honorary consultant medical oncologist, University of Cambridge, discussed second-line therapy for patients with hepatocellular carcinoma.

Britta Stordal, PhD

Latest:

Biomarkers in Ovarian Cancer: Early Detection and Chemoresistance

Worldwide, there are ~204,000 new cases of ovarian cancer each year, accounting for 4% of cancers diagnosed in women.

Brittany Cote

Latest:

Questions Remain Regarding PARP Inhibition in Recurrent Platinum-Sensitive Ovarian Cancer

Joshua G. Cohen, MD, FACOG, FACS, discusses the efficacy of PARP inhibitors in ovarian cancer, remaining questions regarding repeat inhibition and treatment duration, and the potential for combinations.

Brittany Lovely

Managing Editor,

Latest:

DLL3-Targeting Agents Are Poised to Fill Unmet Needs in SCLC

Expression of DLL3, an inhibitor ligand of the Notch pathway associated with tumorigenesis, has emerged as a target of interest for drug development.

Broadgreen University Hospital NHS Trust

Brock O'Neil, MD

Latest:

Dr. O'Neil on Standard of Care in Muscle-Invasive Bladder Cancer

Brock O’Neil, MD, assistant professor, Division of Urology, University of Utah School of Medicine, Huntsman Cancer Institute, discusses the current standard of care in muscle-invasive bladder cancer.

Brock Schroeder, PhD

Latest:

Brock Schroeder Discusses BCI Findings in ER+ Breast Cancer

Brock Schroeder, PhD, senior director, Medical and Scientific Affairs at bioTheranostics, discusses findings regarding the Breast Cancer Index in predicting patients with estrogen receptor (ER)-positive breast cancer at high risk of recurrence.

Bruce Cheson, MD, Georgetown Lombardi Comprehensive Cancer Center

Bruce Cheson, MD, Lombardi Comprehensive Cancer Center

Bruce D. Cheson, MD

Latest:

Dr. Bruce D. Cheson on Obinutuzumab/ Bendamustine Survival Benefit in iNHL

Bruce D. Cheson, MD, Professor of Medicine, Head of Hematology, Deputy Chief, Division of Hematology/Oncology, Georgetown University Hospital, Lombardi Comprehensive Cancer Center, discusses the phase III GADOLIN study, which looks at the anti-CD20 agent obinutuzumab (Gazyva) and bendamustine compared with bendamustine alone in patients with relapsed indolent non-Hodgkin lymphoma (iNHL).

Bruce D. Cheson, MD, FACP, FAAAS, Georgetown University Hospital